But understanding the mechanistic involvement of TFRC and PDLIM3 in drug resistance would be a valuable insight into predicting chemotherapy efficacy and guiding therapeutic strategies for ovarian cancer patients. This evidence concerns the gene TFRC and ovarian carcinoma.